Scarica l'app Stockscreener
28.46
0.18%
0.05
Dopo l'orario di chiusura:
27.95
-0.51
-1.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TEVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm
Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm
Teva stock hits 52-week high at 26.38 USD - Investing.com
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges - Sahm
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Shares: Cheap or Risky? - fostersleader.com
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? - Finviz
Teva Pharma stock hits 52-week high at $25.96 By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at $25.96 - Investing.com
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? - sharewise.com
Why Teva Pharmaceutical Stock Rocked the Market Today - Finviz
Teva Fires on All Cylinders as Innovation and Pipeline Support Growth and Cost-Controls Lift Margins - Morningstar
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Sahm
Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges - Investing.com
Teva stock hits 52-week high at 23.07 USD - Investing.com
Teva stock hits 52-week high at 23.07 USD By Investing.com - Investing.com Philippines
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - Sahm
Earnings call transcript: Teva’s Q2 2025 shows steady growth, stock rises - Investing.com
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
TEVA Stock Price and Chart — VIE:TEVA - TradingView
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - Sahm
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Sahm
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 - Finviz
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm
SciSparc And AutoMax Call Off Merger - Sahm
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm
Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl
Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se
TEVA Stock Price and Chart — TASE:TEVA - TradingView
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com
0.10%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):